ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: FDA Names DeLap Directory Of Oncology

June 7, 1996

CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.

January 21, 2005

PET Response Can Predict Increased Survival In Patients

April 27, 2012

Monica Bertagnolli To Succeed Schilsky As CALGB Chairman.

November 21, 2008

Fourteen Immunology RFPs Announced, NCI will Have Eight More Immunodiagnosis; $43 Million Budgeted

September 6, 1974

Former BMS Executive Bodnar Indicted.

April 25, 2008